This month marks the 16th anniversary of the first full publication of the human genome. Far from being old news, the potential of genomics continues to grow. In what’s already a period of transformation for Life Sciences companies, how can they drive value from genomics, and what are the pitfalls to be avoided?
Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
Digitalization and societal shifts are pushing Life Sciences to the brink of transformation. Over the next decade, successful players will need to redefine their R&D activities in order to rein in expenses, respond to shorter product lifecycles and seize opportunities of personalized medicine.